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Cancer Prevention Research Small Grant
Program (R03)
This program is designed to aid and facilitate the
growth of a cadre of scientists with expertise in can-
cer prevention research. Small grants are short-term
awards that provide support for pilot projects, devel-
opment and testing of new methodologies, or innov-
ative projects that provide a basis for more extended
research.
The NCI Division of Cancer Prevention invites
applications that address developmental research in
chemoprevention agent development, biomarkers,
early detection, and nutrition science, in addition to
clinical studies that focus on specific target organs.
This scientiﬁc initiative (funding opportunity) is not
intended for the support of research grant applica-
tions that are focused on treatment, etiology, and/or
treatment-related general quality of life studies that
are population based. The speciﬁc areas of research
may include, but are not limited to:
Early detection. 1) identiﬁcation, development,
and evaluation of biological analytic techniques,
methodologies, and clinical technologies relevant to
preclinical cancer detection and prevention of pri-
mary and recurrent cancers; 2) cellular, molecular,
and genetic tumor markers; 3) molecular epidemiol-
ogy and genetic risk factors; 4) imaging technology;
5) identification of molecular signatures of cancer-
associated infectious agents for earlier cancer detec-
tion and risk assessment; 6) transfer of basic
laboratory ﬁndings into applications for early detec-
tion with the goal of extending this research to com-
parative clinical trials; 7) development and
evaluation of new high-throughput genomic- and
proteomic-based detection techniques as well as of
measures of sensitivity, specificity, validity, and
safety; 8) performance of translational research to
facilitate the transfer of new technologies (to the
clinical setting) for earlier detection, prevention,
and risk assessment; 9) development and evaluation
of computer-based data monitoring systems for
analysis and interpretation of laboratory data on
multiple markers of and for the development of
modeling systems based on molecular, genetic, and
other risk factors to be used in the evaluation of
cancer prevention approaches; 10) definition and
evaluation of prognostic factors of precancerous
lesions by computer models that include neural net-
works, artificial intelligence, and other techniques;
and 11) development of analytic techniques to iden-
tify populations that may be at increased risk as
indicated by genetic and metabolic phenotypes (sus-
ceptibility markers).
Chemoprevention. 1) pilot testing and develop-
ment of new methods of chemoprevention, dietary,
or nutrition intervention; 2) development and eval-
uation of molecular targets to prevent, reverse, or
retard progression of precancerous lesions (and
hence the cancer process) by natural, synthetic,
chemopreventive agents; 3) feasibility and efficacy
testing of rapid screening methods to identify and
prioritize new chemopreventive agents; 4) testing of
new strategies to prevent cancer or its progression in
persons at increased genetic risk; 5) development of
innovative animal models to mimic the human can-
cer process in order to expedite research in cancer
prevention; and 6) investigation of mechanisms of
action of chemopreventive agents.
Nutrition. 1) improvements in methodology
development for assessing nutritional status, meta-
bolic patterns, and dietary modulation of genetic
expression; 2) identiﬁcation, development, and vali-
dation of biochemical or biological markers for mea-
suring and monitoring dietary compliance and
exposure; 3) development of reliable methods for
analysis of nutrients, other dietary components, and
their metabolites in foods, body fluids, and tissues;
4) development of mechanistic studies of dietary con-
stituent interactions, gene–nutrient interactions, and
dietary environmental factor interactions; 5) identiﬁ-
cation and evaluation of molecular targets to prevent,
reverse, or retard progression of precancerous lesions
(and hence the cancer process) by dietary/nutritional
interventions; 6) determination of bioavailability and
dose response of foods, nutrients, and other naturally
occurring food constituents; and 7) although the spe-
ciﬁc study proposed may attempt only to obtain pre-
liminary data and/or conduct pilot studies in support
of a future, more detailed clinical study, it is impor-
tant that a long-term human cancer prevention
hypothesis and supporting scientiﬁc justiﬁcation be
presented.
This program is designed to increase the basic
and applied scientific knowledge of cancer preven-
tion research, and to enhance community-based
clinical research in cancer prevention.
The common characteristic of the NIH R03
small grant is provision of limited funding for a
short period of time. Examples of the types of pro-
jects that NIH ICs support with the R03 include
the following: 1) pilot or feasibility studies; 2) sec-
ondary analysis of existing data; 3) small, self-con-
tained research projects; 4) development of research
methodology; 5) development of new research tech-
nology; 6) nature of the research opportunity;
7) pertinent background information that estab-
lishes the need for the research; 8) scientiﬁc knowl-
edge to be achieved through research supported by
the special program; 9) objectives of this research
program; and 10) identification of the types of
research and experimental approaches being sought
to achieve the objectives.
This Funding Opportunity Announcement
(FOA) will use the NIH Small Grants Program
(R03) award mechanism. As an applicant, you will
be solely responsible for planning, directing, and
executing the proposed project. The total budget
may not exceed $100,000 in direct costs for the
entire project. The direct costs in any one year must
not exceed $50,000. Please note that facilities and
administrative [F&A] costs requested by any con-
sortium participants are excluded from the direct
cost limit per NIH Guide Notice NOT-OD-04-
040 (http://grants.nih.gov/grants/guide/notice-ﬁles/
NOT-OD-04-040.html).
The total project period for an application sub-
mitted in response to this program announcement
may not exceed 2 years. NIH policy limits the num-
ber of amendments that may be submitted to two.
The small grant is not renewable.
This FOA uses just-in-time concepts. It also
uses the modular budget formats (see the “Modular
Applications and Awards” section of the NIH
Grants Policy Statement). Specifically, if you are
submitting an application with direct costs in each
year of $250,000 or less (excluding consortium
Facilities and Administrative [F&A] costs), use the
PHS398 Modular Budget component provided in
the SF424 (R&R) Application Package and SF424
(R&R) Application Guide (see specifically Section
5.4, “Modular Budget Component,” of the
Application Guide).
Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached
to a speciﬁc FOA can be used. You will not be able
to use any other SF424 (R&R) forms (e.g., sample
forms, forms from another FOA), although some of
the "Attachment" files may be useable for more
than one FOA.
For further assistance, contact GrantsInfo, 301-
435-0714, (telecommunications for the hearing
impaired: TTY 301-451-0088), or by e-mail:
GrantsInfo@nih.gov.
The application submission dates for this PAR
are 21 July 2007, and 20 December 2007. 
Contacts: The complete list of agency contacts
is available at http://grants.nih.gov/grants/guide/pa-
ﬁles/PAR-06-313. Reference: PAR-06-313.
Translational Research for the Prevention and
Control of Diabetes and Obesity (R18)
Several large, controlled clinical trials have estab-
lished "gold standard" approaches for treating type 1
and type 2 diabetes, and for preventing or delaying
type 2 diabetes in individuals at high risk for devel-
oping the disorder. Research is needed to translate
the results of these trials into widespread practice.
Studies to develop effective, sustainable, and cost-
effective methods to prevent and treat diabetes and
obesity in clinical health care practice and other real-
world settings are appropriate targets for transla-
tional research.
The Diabetes Control and Complications Trial
(DCCT), for type 1 diabetes, and the United
Kingdom Prospective Diabetes Study (UKDPS), for
type 2 diabetes, established the importance of inten-
sive glycemic control in dramatically reducing the
devastating complications of diabetes.
Unfortunately, the therapies proven to delay or
prevent complications in these studies have not
been widely incorporated into general health care
practice. Prevention and treatment of long-term
micro- and macrovascular complications remain a
critical problem in the management of type 1 and
type 2 diabetes mellitus. In the United States, dia-
betes is the leading cause of new blindness in work-
ing-age adults, of new cases of end-stage renal
disease, and of nontraumatic lower leg amputations.
In addition, cardiovascular complications are now
the leading cause of diabetes-related morbidity and
mortality, particularly among women and the
elderly. In adults with diabetes, the risk of cardio-
vascular disease (CVD) is 2- to 4-fold greater than
in nondiabetics. Comorbid conditions (hyperten-
sion, dyslipidemia, and smoking) combine with
hyperglycemia to contribute to accelerated athero-
sclerosis. Clinical trial data have established the
unequivocal beneﬁt of rigorous control of glycemia
and blood pressure in preventing both micro- and
macrovascular complications of diabetes. Smoking
cessation, aspirin therapy, and lipid control have
also been shown to prevent morbidity. Despite
clear-cut evidence of beneﬁt, recently available data
demonstrate that patients with diabetes are not
achieving recommended levels of glycemic, blood
pressure, or lipid control, or adherence to other
accepted treatment guidelines.
The difﬁculties inherent in achieving good glu-
cose control and preventing diabetes complications
make prevention a compelling strategy. This is par-
ticularly true for type 2 diabetes, which is clearly
linked to modiﬁable risk factors, e.g., overweight or
obesity and a sedentary lifestyle. The Diabetes
Prevention Program (DPP) tested strategies to pre-
vent or delay the development of type 2 diabetes in
individuals at high risk for its development by virtue
of their having impaired glucose tolerance (IGT).
The DPP demonstrated that intensified lifestyle or
drug intervention in individuals with IGT prevented
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or delayed the onset of type 2 diabetes. Lifestyle
intervention, leading to moderate weight loss and
increased exercise, reduced diabetes incidence by
58% and the drug metformin by 31% compared
with placebo. The effects were similar for men and
women and for all racial and ethnic groups. Similar
effects of lifestyle intervention were seen in another
study conducted in Finland. Cost-effective strategies
for promoting lifestyle modification leading to
weight loss in these high-risk individuals, outside the
setting of a controlled, clinical trial, need to be estab-
lished. In addition, while behavioral treatment of
obesity in adults leads to clinically signiﬁcant weight
loss, prevention of weight regain remains an elusive
goal for many.
Overweight in childhood, the prevalence of
which has more than doubled in the past 2 decades,
is a major risk factor for type 2 diabetes. Indeed, the
increase in overweight children has been linked to a
rise in type 2 diabetes in the pediatric population.
Family-based behavioral interventions have been
shown to have a long-term impact on degree of over-
weight. However, cost-effective interventions in pri-
mary care and community-based settings are needed.
One-third of people with type 2 diabetes are
undiagnosed. In addition a signiﬁcant proportion of
patients are diagnosed with diabetes only when they
present with diabetic retinopathy or neuropathy.
Epidemiologic data have shown that the risk for com-
plications increases with duration of diabetes. Thus
early diagnosis and treatment likely decreases the risk
for complications. Population-based as well as gener-
alizable, clinic-based strategies are needed to establish
cost-effective programs to identify individuals at risk
for diabetes or who have diabetes who could beneﬁt
from prevention or treatment programs.
The National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) through
this FOA seeks to foster the development of cost
effective and sustainable translational research stud-
ies to prevent and treat obesity and diabetes. The
interventions designed should have the potential to
be disseminated to clinical practice including indi-
viduals or communities at risk. It is not the intent of
this FOA to support the development of initial efﬁ-
cacy trials. Rather, it is for the translation of inter-
ventions that have previously been shown to be
efﬁcacious in the research setting. Proposed studies
must address issues of sustainability, cost-effective-
ness, and dissemination. Interventions should be as
close to cost-neutral as possible. Studies addressing
minority populations at disproportionate risk for
obesity, diabetes, and diabetes complications are
encouraged. These proposals should focus on novel
approaches to health care delivery and diabetes pre-
vention. Proposals in which the main focus is on
development and validation of culturally appropriate
materials are not considered responsive.
Study design and its accompanying analysis plan
must be linked to the research question. The general
goal is to select a design that maximizes generalizabil-
ity and minimizes bias. Relevant topics include, but
are not limited to: 1) strategies to enhance glycemic
control and reduce risk factors for the development of
the complications of type 1 or type 2 diabetes such as
blood pressure and lipids; 2) strategies to promote the
adoption of healthy lifestyles which will reduce obe-
sity and diabetes; 3) strategies for less burdensome and
more cost-effective methods to identify those with or
at risk of prediabetes and/or type 2 diabetes; 4) studies
that test interventions to enhance long-term mainte-
nance of weight loss and prevention of weight regain
after weight loss; 5) studies to test approaches for cost-
effective delivery of diabetes education and self-
management instruction for improvement of
glycemia; 6) studies that test interventions to treat
childhood and adolescent overweight in primary care
or community settings; 7) strategies to overcome
health care system barriers that reduce the efﬁciency
or effectiveness of patient/provider interaction and
health outcomes; 8) strategies to promote the adop-
tion of healthy lifestyles in women with or at risk for
the development of GDM; 9) studies of interventions
in work place settings or managed care organizations.
Of particular interest are studies to improve
self-management and enhance health care delivery to
underserved and minority populations. Such studies
may seek to improve outcomes in populations (with
either type 1 or type 2 diabetes) that historically have
had poor glycemic, blood pressure, and other risk
factor control, or promote effective prevention
strategies in minority populations known to be at
high risk for the development of type 2 diabetes
and/or its complications.
Applicants who have received awards in response
to PAR-06-358 (Planning Grants for Translational
Research for the Prevention and Control of Diabetes
and Obesity) should clearly identify how the Planning
Grant–generated pilot and feasibility data has led to
and supports the full-scale R18 proposal. Investigators
who require a planning and pilot data collection phase
should utilize PAR-06-358 prior to submission of an
R18 proposal. All applicants should provide the ratio-
nale for the large-scale intervention and provide a full
description of the setting for delivery of the interven-
tion, primary and secondary outcomes to be assessed,
the duration of follow-up, and the statistical analysis
to be employed. Investigators must also address cost-
effectiveness and sustainability of the proposed study
design. For the project to be supported under the
R18, applicants should also provide a detailed descrip-
tion of the target population to be studied, with justi-
ﬁcation, including a deﬁnition of the cohort by age,
sex, and race/ethnicity. The applicant’s experience in
recruiting this target population and the methods to
be used should be described. Sample size needs
required and assumptions made to estimate an appro-
priate sample size should be detailed including the
analysis plan to be used. Applicants must state their
plans for reporting accrual by sex, race, and ethnicity
and for the reporting of results that examine differ-
ences in treatment effects across these subgroups (see
"Inclusion of Women and Minorities in Research
Involving Human Subjects"). Methods for assuring
privacy and maintaining confidentiality should be
included. A data and safety monitoring plan must be
included.
Studies may utilize methodology from the
fields of biomedical, social, or behavioral sciences,
epidemiology, clinical trials, and health services and
dissemination research. The primary outcome
should include glycemia or weight. An intervention
aimed at producing a behavioral change should be
grounded in behavior change theory, which should
be incorporated into the intervention. The applica-
tion will be strengthened by the inclusion of a
process evaluation, i.e., an evaluation of whether the
intervention is actually delivered as intended. It is
also recommended that applicants review the con-
tents of the translational research meeting report
URL at http://www.niddk.nih.gov/fund/other/
Diabetes-Translation/conf-publication.pdf.
Investigators should provide detailed evidence
that the research team has the experience and exper-
tise to conduct the research study. Most transla-
tional research will require a multidisciplinary
research team. Thus, a variety of researchers may be
required for these studies, including, but not limited
to, endocrinologists, public health physicians, pri-
mary care physicians, epidemiologists, statisticians,
psychologists, health educators, sociologists, nurses,
nutritionists, and other health-related professionals.
The interdisciplinary nature of the research team
should be fully described and justiﬁed.
Brief descriptions, as appropriate, of the process
for biologic sample collection, storage, and handling;
the laboratory tests that are needed; physical facili-
ties, data management, and computer resources, and
facilities for data retrieval and storage; and a plan for
randomization of patients or settings for delivery of
interventions into protocols should be provided.
Investigators located at existing Diabetes
Research and Training Centers (DRTC) or propos-
ing to collaborate with a DRTC should include a
complete description of how the proposal in
response to this PAR will utilize the core facilities
funded through the DRTC. Investigators who are
not directly afﬁliated with a DRTC may, if feasible,
form collaborations with such centers to utilize the
core resources. A list of DRTCs can be found at
http://www.niddk.nih.gov/fund/other/centers.htm.
Investigators located at existing CDC-DDT
supported "Translating Research into Action for
Diabetes (TRIAD)" sites should include a full
description of how the TRIAD sites will be advanta-
geously utilized. TRIAD investigators should also
describe how they will integrate the TRIAD sites
and cohort without adversely affecting or overlap-
ping the current and future multicenter collabora-
tive goals of the TRIAD Study (e.g., primary
hypotheses, cohort follow-up). The testing of inter-
ventions to prevent or treat disease among individu-
als from the TRIAD cohort is encouraged.
Interaction is encouraged between NIH-
funded investigators and investigators at CDC
Prevention Research Centers, a national network of
28 academic research centers that engage communi-
ties as participants in research on preventing chronic
diseases. Information about CDC prevention
research centers may be found at http://www.cdc.
gov/prc/index.htm. In addition, applicants may be
interested in the messages and resources already
developed by the National Diabetes Advisory Board
(NDEP) and available on the NDEP web site at
http://www.ndep.nih.gov/.
This FOA will use the NIH Research
Demonstration and Dissemination Project (R18)
award mechanism.  
The applicant will be solely responsible for
planning, directing, and executing the proposed
project. 
This FOA uses “Just-in-Time” information con-
cepts. It also uses the nonmodular budget formats.
Applicants must download the SF424 (R&R)
application forms and the SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached
to a speciﬁc FOA can be used. You will not be able
to use any other SF424 (R&R) forms (e.g., sample
forms, forms from another FOA), although some of
the "Attachment" files may be useable for more
than one FOA.
For further assistance, contact GrantsInfo: 301-
435-0714, (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
The application submission dates for this PA
are available at http://grants.nih.gov/grants/
funding/submissionschedule.htm. 
The complete version of this PAR is available at
http://grants.nih.gov/grants/guide/pa-files/
PAR-06-457.html.
Contacts: The complete list of agency contacts
is available at http://grants.nih.gov/grants/guide/
pa-ﬁles/PAR-06-457. Reference: PAR-06-457.